Group 1 - The core point of the article is that Jianzhijia (SH 605266) announced a pledge extension of shares by its major shareholder Wang Yanping, who holds approximately 15.46 million shares, accounting for 10.01% of the total share capital [1] - After the pledge extension, Wang Yanping has pledged a total of 1.45 million shares, which is 9.38% of her holdings and 0.94% of the company's total shares [1] - For the first half of 2025, Jianzhijia's revenue composition is as follows: 90.17% from pharmaceutical retail and services, 5.51% from other businesses, 4.17% from convenience retail, and 0.15% from pharmaceutical wholesale [1] Group 2 - As of the report, Jianzhijia has a market capitalization of 3.3 billion yuan [2] - The Chinese innovative drug sector has seen significant overseas licensing sales, totaling 80 billion USD this year, indicating a hot secondary market in biomedicine [2]

Group 1 - The core viewpoint of the article is that Jianzhijia (SH 605266) held its 12th meeting of the 6th Board of Directors on August 28, 2025, to review the agenda including the 2025 semi-annual report and its summary [1] - For the first half of 2025, Jianzhijia's revenue composition was as follows: 90.17% from pharmaceutical retail and services, 5.51% from other businesses, 4.17% from convenience retail, and 0.15% from pharmaceutical wholesale [1]